Laura Kyle Brett, M.D., is board certified in medical oncology, hematology and internal medicine. Patient comments about her include:
"She shakes your hand when she enters the room. She takes time with you and is never in a hurry. Her nurses are very kind, polite and understanding. It's just an awesome team Dr. Brett has! She is an excellent doctor and is always there for my family when they have questions or concerns."
"I am 97 years old and have had quite a few doctors. She is one of the best I have had. I can believe her. She is the best. She takes care of her people. You could not ask for better!"
"Dr. Brett asked me thorough questions, looked at my x‐rays and went over every detail that was a concern. She was very reassuring about my condition and I left satisfied with the results. She further explained how we were going to care for my medical issues in the future. I left in a great state of mind and relieved! Dr. Brett and her staff provided me with exemplary and professional care. My experience was comforting and pleasant. I am very pleased!"
She is a member of the Alpha Omega Alpha Honor Medical Society.
Dr. Brett is a Tulsa native and graduated from Booker T. Washington High School. She earned a Bachelor of Science degree in biology at Duke University in Durham, North Carolina in 2002. She received her Doctor of Medicine degree at the Wake Forest University School of Medicine in Winston-Salem, North Carolina in 2008. She completed her internal medicine residency in 2011 and her oncology and hematology fellowships in 2014, all at the University of Virginia in Charlottesville, Virginia, where she served as chief fellow.
Her peer-reviewed publications include:
Jayappa KD, Portell CA, Gordon VL, Capaldo BJ, Bekiranov S, Axelrod MJ, Brett LK, Wulfkuhle JD, Gallagher RI, Petricoin EF, Bender TP, Williams ME, Weber MJ. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv. 2017 Jun 13;(1(14):933-946
Murphy PW, Brett LK, Verla-Tebit E, Macik BG, Loughran TP Jr. Acquired inhibitors to factor VIII and fibrinogen in the setting of T-cell large granular lymphocyte leukemia: a case report and review of the literature. Blood Coagul Fibrinolysis. 2015 Mar;26(2):211-3
Axelrod M, Ou Z, Brett LK, et al. Combinatorial drug screening identifies synergistic co-targeting of Bruton’s tyrosine kinase and the proteasome in mantle cell lymphoma. Leukemia 2014;28:407-410.
Brett LK, Williams ME. Current and emerging therapies in mantle cell lymphoma. Curr Treat Options Oncol. 2013 Jun;14(2):198-211
Brett K, Parker R, Wittenauer S, Hayashida K, Young T, Vincler M. Impact of chronic nicotine on sciatic nerve injury in the rat. J Neuroimmunol. 2007 May;186(1-2):37-44.
Dr. Brett’s personal interests include reading, hiking, knitting and spending time with her family.
Dr. Brett welcomes new oncology and hematology patients. While she is particularly skilled in the areas of lymphomas (particularly mantle cell lymphoma), chronic leukemia, multiple myeloma, lung cancer and malignant melanoma, she would be glad to provide you with any cancer-related care. She accepts most insurance plans. Her office is located on the campus of Hillcrest Medical Center at:
Utica Park Clinic
1245 S. Utica Ave., Suite 100
Tulsa, OK 74104
For more information or to schedule an appointment, call 918-579-3850 between 8:00 a.m. and 5:00 p.m., Monday through Friday.